The ALK mutation is known as the “diamond mutation,” and treatments for ALK rearrangement-positive nonsmall cell lung cancer recommend alectinib, brigatinib, or lorlatinib as first-line therapy, with ceritinib or ceritinib as secondary alternatives. Here, ALK is linked to lung cancer.